Biofrontera (NASDAQ:BFRI – Get Free Report) and Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.
Profitability
This table compares Biofrontera and Amicus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biofrontera | -36.31% | -565.73% | -96.64% |
| Amicus Therapeutics | -21.21% | -15.97% | -3.17% |
Earnings & Valuation
This table compares Biofrontera and Amicus Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biofrontera | $34.07 million | 0.24 | -$20.13 million | ($2.26) | -0.47 |
| Amicus Therapeutics | $399.36 million | 7.00 | -$151.58 million | ($0.34) | -27.53 |
Analyst Ratings
This is a summary of recent ratings and target prices for Biofrontera and Amicus Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biofrontera | 0 | 0 | 1 | 0 | 3.00 |
| Amicus Therapeutics | 0 | 2 | 7 | 0 | 2.78 |
Biofrontera currently has a consensus price target of $7.00, indicating a potential upside of 560.38%. Amicus Therapeutics has a consensus price target of $16.88, indicating a potential upside of 80.29%. Given Biofrontera’s stronger consensus rating and higher possible upside, equities analysts plainly believe Biofrontera is more favorable than Amicus Therapeutics.
Risk and Volatility
Biofrontera has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
Institutional and Insider Ownership
10.1% of Biofrontera shares are held by institutional investors. 0.2% of Biofrontera shares are held by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Amicus Therapeutics beats Biofrontera on 9 of the 14 factors compared between the two stocks.
About Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
